4.5 Article

Potential opportunities and perils of imperfect dengue vaccines

Journal

VACCINE
Volume 32, Issue 4, Pages 514-520

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2013.11.020

Keywords

Dengue vaccine; Vaccine effects; Mathematical model

Funding

  1. Bill and Melinda Gates Foundations Vaccine Modeling Initiative
  2. National Institutes of Health (NIH) [1U54GM088491]
  3. National Institute Of General Medical Sciences [R01GM090204]
  4. Burroughs Wellcome Fund
  5. Office of Naval Research

Ask authors/readers for more resources

Dengue vaccine development efforts have focused on the development of tetravalent vaccines. However, a recent Phase lib trial of a tetravalent vaccine indicates a protective effect against only 3 of the 4 serotypes. While vaccines effective against a subset of serotypes may reduce morbidity and mortality, particular profiles could result in an increased number of cases due to immune enhancement and other peculiarities of dengue epidemiology. Here, we use a compartmental transmission model to assess the impact of partially effective vaccines in a hyperendemic Thai population. Crucially, we evaluate the effects that certain serotype heterogeneities may have in the presence of mass-vaccination campaigns. In the majority of scenarios explored, partially effective vaccines lead to 50% or greater reductions in the number of cases. This is true even of vaccines that we would not expect to proceed to licensure due to poor or incomplete immune responses. Our results show that a partially effective vaccine can have significant impacts on serotype distribution and mean age of cases. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available